Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Pulls Prochieve From Guidance, But Pushes For Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite a disappointing advisory committee review for its progesterone gel for preterm birth, Watson said it will continue to push for approval. The company also bolsters its Australian generics business with the acquisition of Ascent.

Advertisement

Related Content

Regulatory News, In Brief
Watson May Bypass Progesterone Gel 8% For Second-Generation Product
Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
Watson Pharma Defends Ascent Buyout; Bigger Scale Will Offset Price Cuts In Australia
Watson Talks Up Prochieve And Global Expansion At Analyst Meeting

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel